Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Nordea Bank Abp in connection with a tap issue of SEK 100 million hybrid bonds.
Mandate

Vinge has advised Nordea Bank Abp in connection with a tap issue of SEK 100 million hybrid bonds.

November 01, 2018 Banking and Finance

Vinge has advised Nordea Bank Abp (“Nordea”) in connection with Samhällsbyggnadsbolaget i Norden AB (publ) (”SBB”) tap issue of SEK 100 million hybrid bonds under the Company’s existing framework of up to SEK 1500 million.

The hybrid bonds are perpetual and currently carry a floating interest rate of STIBOR 3M + 6.35 per cent. Nordea has acted as financial advisor to SBB and as issuing agent.

In accordance with the terms and conditions, the subsequent bonds are intended to be listed and admitted to trading on the corporate bond list at Nasdaq Stockholm shortly.

Vinges team consisted of Mikael Ståhl and Lionardo Ojeda.
 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024